AbbVie lands FDA approval for next-generation Parkinson’s drug, Juvmo

Juvmo was designed to offer a reduction in motor symptoms, while reducing non-motor side effects, through its more selective ...
The Brighterside of News on MSN

Long-term air pollution exposure linked to Parkinson’s disease risk

A Cambridge review links long-term particle pollution with increased Parkinson’s risk while highlighting major research gaps.
CoinCentral

AbbVie (ABBV) Stock: FDA Approves New Parkinson’s Drug Juvmo

AbbVie stock (ABBV) slipped slightly on Monday, down 0.29%, after the company announced a major regulatory win. The FDA ...
Fierce Pharma

AbbVie's Cerevel buyout delivers as FDA gives go-ahead to 1st-in-class Juvmo in Parkinson's disease

Although a clinical setback last year continues to loom in the background, AbbVie’s $8.7 billion bet on Cerevel Therapeutics ...
BIOENGINEER

Parkinson’s Doubles Hip Fracture Risk, Yet Osteoporosis Drugs Are No More Likely After Breaks

A nationwide Finnish cohort study found that people with Parkinson's disease receive anti-osteoporosis medications at rates ...
AbbVie News Center

U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease

JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients ...
Health and Me on MSN

CSIR-CCMB scientists find flu & COVID viruses may affect a protein linked to Parkinson’s disease

Researchers at CSIR-Centre for Cellular and Molecular Biology (CCMB) have found possible links between RNA viruses like ...

AskBio’s bold ambition to help people with Parkinson’s disease look forward — and maybe even tango

"Among the aims of the research team is to better understand whether gene therapy may one day provide a different approach to ...